Cancers presenting with the higher percentage of lesions in CTCF: Uterine endometrial carcinomas (37.25% of total samples have CTCF lesions), ovarian serous carcinomas (16.5% of total samples with CTCF lesions), bladder carcinomas (13.61% of total samples with CTCF lesions), colorectal carcinomas (11.24% of total samples with CTCF lesions), and prostate cancers (10.79% of total samples with CTCF lesions) (Table 1). Here, CTCF is linked to prostate carcinoma.